Trial
NCT02556086
A Phase 2b Evaluation of Daclatasvir/Sofosbuvir in Non-Cirrhotic Treatment Naive Subjects With Genotype 1, 2, 3 and 4 Chronic Hepatitis C Virus Coinfected With Human Immunodeficiency Virus (HIV-1)
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
Bristol-Myers Squibb
Collaborators
—
Condition
Hepatitis C
Intervention
Daclatasvir
Why stopped
—
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2016-01-20